BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 668190)

  • 1. Spontaneous lymphocyte proliferation and depressed cellular immunity in Hodgkin's disease.
    Shiftan TA; Caviles AP; Mendelsohn J
    Clin Exp Immunol; 1978 Apr; 32(1):144-52. PubMed ID: 668190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes.
    Hillinger SM; Herzig GP
    J Clin Invest; 1978 Jun; 61(6):1620-7. PubMed ID: 149140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes.
    Matchett KM; Huang AT; Kremer WB
    J Clin Invest; 1973 Aug; 52(8):1908-17. PubMed ID: 4541673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide.
    Fisher RI; Bostick-Bruton F
    J Immunol; 1982 Oct; 129(4):1770-4. PubMed ID: 6980949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity.
    Passwell J; Levanon M; Davidsohn J; Ramot B
    Clin Exp Immunol; 1983 Jan; 51(1):61-8. PubMed ID: 6572580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blastogenic transformation of lymphocytes following phytohaemagglutinin treatment in vitro in malignant lymphomas. I. Hodgkin's disease. (Correlation with immunity response of the cellular type and with the clinical status).
    Libánský J; Lukásová M; Pinosová I
    Neoplasma; 1973; 20(1):51-60. PubMed ID: 4702205
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune status of untreated patients with Hodgkin's disease and prognosis.
    Björkholm M; Wedelin C; Holm G; Ogenstad S; Johansson B; Mellstedt H
    Cancer Treat Rep; 1982 Apr; 66(4):701-9. PubMed ID: 7074640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
    Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
    J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune function of successfully treated lymphoma patients.
    King GW; Yanes B; Hurtubise PE; Balcerzak SP; LoBuglio AF
    J Clin Invest; 1976 Jun; 57(6):1451-60. PubMed ID: 932190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro evidence of normal lymphocyte function in some patients with Hodgkin's disease and negative delayed cutaneous hypersensitivity.
    Churchill WH; Rocklin RR; Moloney WC; David JR
    Natl Cancer Inst Monogr; 1973 May; 36():99-106. PubMed ID: 4583000
    [No Abstract]   [Full Text] [Related]  

  • 11. Monocyte function in Hodgkin's disease.
    Holm G; Björkholm M; Johansson B; Mellstedt H; Lindemalm C
    Clin Exp Immunol; 1982 Jan; 47(1):162-8. PubMed ID: 7094420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed lymphocyte culture stimulatory and responding capacity of lymphocytes from patients with lymphoproliferative diseases.
    Rühl H; Vogt W; Bochert G; Schmidt S; Moelle R; Schaoua H
    Clin Exp Immunol; 1975 Jan; 19(1):55-65. PubMed ID: 128426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte reactivity to phytohaemagglutinin and allogeneic lymphocytes in 32 untreated patients with Hodgkin's disease.
    Lang JM; Oberling F; Bigel P; Mayer S; Waitz R
    Biomedicine; 1974 Sep; 21(9):372-7. PubMed ID: 4281669
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hodgkin's disease--immunological aspects].
    Plat M; Frank KH; Fleischer J; Plat U; Koslowski R
    Allerg Immunol (Leipz); 1988; 34(3):139-58. PubMed ID: 3057835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of cell subpopulations mediating mitogen hyporesponsiveness in patients with Hodgkin's disease.
    Sibbitt WL; Bankhurst AD; Williams RC
    J Clin Invest; 1978 Jan; 61(1):55-63. PubMed ID: 304068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
    Levo Y; Rotter V; Ramot B
    Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persisting lymphocyte deficiences during remission in Hodgkin's disease.
    Björkholm M; Holm G; Mellstedt H
    Clin Exp Immunol; 1977 Jun; 28(3):389-93. PubMed ID: 302164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease. Their relationship to immune function.
    Spinozzi F; Velardi A; Rambotti P; Losito A; Zampi I; Cernetti C; Gerli R; Martelli MF; Grignani F
    J Clin Lab Immunol; 1983 Oct; 12(2):87-92. PubMed ID: 6644793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological capacity of lymphocytes from untreated patients with Hodgkin's disease evaluated in mixed lymphocyte culture.
    Björkholm M; Holm G; Mellstedt H; Pettersson D
    Clin Exp Immunol; 1975 Dec; 22(3):373-7. PubMed ID: 131665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous production of an inhibitor in vitro lymphocyte migration by lymphocytes from patients with Hodgkin's disease and mycosis fungoides.
    Skopińska-Rónzewska E; Zółtowska A; Dziewulska-Bokiniec A
    Arch Immunol Ther Exp (Warsz); 1982; 30(1-2):57-62. PubMed ID: 6756337
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.